Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants

Bronchiolitis Clinical Trial

Official title:

Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants: A Randomized, Double Blind, Controlled Trial (RCT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01435486
• Other study ID #: #11146/11
• Status: Completed
• Phase: N/A
• First received: September 8, 2011
• Last updated: March 31, 2015
• Start date: November 2011
• Est. completion date: November 2014

Study information

• Verified date: May 2014
• Source: Hamad Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Qatar: Hamad Medical Corporation
• Study type: Interventional

Clinical Trial Summary

Viral bronchiolitis is the most common lower respiratory tract infection of infancy. Apnea is a complication of bronchiolitis, reported in 16 - 21% of cases. Caffeine, a trimethylxanthine, acts as an antagonist to endogenous adenosine and a potent central nervous system stimulant. In apnea of prematurity, caffeine is believed to work by increasing central respiratory drive.

Infants ≤4 months of age, presenting to pediatric emergency center Al-Sadd, from September 2011 to May 2014, with a diagnosis of viral bronchiolitis associated with apnea.

A randomized, double-blind, controlled trial with a sample size of 45 patients per group

Data Collection methods, instruments used measurements:

Randomization:

In the emergency department, the patients will be assigned to either one of the two treatments using a computer-generated randomized numbers in a 1:1 ratio. Pharmacy will prepare sequential sealed vials containing the experimental drugs. Randomization code will be revealed only after all patients completed the study. The medical team in addition to the patients will be blinded to the medication delivered. There will be no detectable difference in the color, smell of the two study treatments.

Guardians or parents of eligible infants will be approached regarding the study, explaining the purpose and the treatment modalities. Patients will be included after obtaining a verbal and written consent.

Study Intervention:

Treatment 1: Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).

Treatment 2: Placebo with an equivalent volume of normal saline. Calculated study medications will be diluted with Dextrose 5% in Water to 20 ml and will be given intravenous over 30 minutes using syringe infusion pump.

After random assignment, eligible infants will receive one of the study treatments. Non-pharmacological therapies may be used as necessary to control apnea. Antibiotics and antipyretics may be used as per the discretion of the treating physician.

After stabilization of patients as usually done in Pediatric Emergency Center , patients will be admitted to pediatric intensive care unit (PICU) for further monitoring monitoring when indicated.

Description:

Study area/setting:

Pediatric emergency center Al-Sadd, (PEC) is the main pediatric emergency centre in the state of Qatar with approximately 200,000 visits annually. It has a capacity of 42 observation beds providing most of the inpatient facilities except for intensive care monitoring. Patients admitted to the Pediatric Emergency Center are managed there until discharged home unless an Intensive Care Unit admission is required.

Study Subjects:

• Inclusion criteria: Infants ≤4 months of age, presenting to pediatric emergency center Al-Sadd, from September 2011 to May 2014, with a diagnosis of viral bronchiolitis associated with apnea.

• Exclusion criteria:

• Hypersensitivity to caffeine.

• Patients on caffeine treatment.

• Cardiovascular congenital abnormalities.

• Infants with a previous diagnosis of gastroesophageal reflux disease.

• Hypoglycemia and/or electrolytes disorders.

• Suspected sepsis.

• Seizure disorders.

• Inborn errors of metabolism.

• Renal and/or hepatic impairment.

• Major congenital anomalies of the upper and lower respiratory tract (severe tracheomalacia, trachea-esophageal fistula, diaphragmatic hernia, congenital lobar emphysema, congenital cystic adenomatoid malformation).

Study Design: A randomized, double-blind, controlled trial.

Sample Size:

In a retrospective chart review for all patients admitted to our institutions PICU/step-down unit with bronchiolitis associated with apnea in 2010, 87 patients were identified, 52 patients (60%) were apnea free after 12 hours from admission. To enable detection of a 50% improvement for the investigated group in resolution of apnea after 12 hours with 90% power and two sided alpha= 0.05, we estimated 42 patients per group is required. To compensate for dropouts, we planned to recruit 90 patients altogether.

Data Collection methods, instruments used measurements:

Randomization:

In the emergency department, the patients will be assigned to either one of the two treatments using a computer-generated randomized numbers in a 1:1 ratio. Pharmacy will prepare sequential sealed vials containing the experimental drugs. Randomization code will be revealed only after all patients completed the study. The medical team in addition to the patients will be blinded to the medication delivered. There will be no detectable difference in the color, smell of the two study treatments.

Guardians or parents of eligible infants will be approached regarding the study, explaining the purpose and the treatment modalities. Patients will be included after obtaining a verbal and written consent.

Study Intervention:

Treatment 1: Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).

Treatment 2: Placebo with an equivalent volume of normal saline.

Calculated study medications will be diluted with D5W to 20 ml and will be given intravenous over 30 minutes using syringe infusion pump.

After random assignment, eligible infants will receive one of the study treatments. Non-pharmacologic therapies such as supplemental oxygen, non invasive respiratory support, endotracheal intubation and mechanical ventilation may be used as necessary to control apnea. Antibiotics and antipyretics may be used as per the discretion of the treating physician.

After stabilization of patients as usually done in pediatric emergency center , patients will be admitted to Pediatric Intensive Care Unit for further monitoring when indicated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: November 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 4 Months

Eligibility

Inclusion Criteria:

• Infants =4 months of age, presenting to pediatric emergency center Al-Sadd, from September 2011 to May 2014, with a diagnosis of viral bronchiolitis associated with apnea.

Exclusion Criteria:

• Hypersensitivity to caffeine.

• Patients on caffeine treatment.

• Cardiovascular congenital abnormalities.

• Infants with a previous diagnosis of gastroesophageal reflux disease.

• Hypoglycemia and/or electrolytes disorders.

• Suspected sepsis.

• Seizure disorders.

• Inborn errors of metabolism.

• Renal and/or hepatic impairment.

• Major congenital anomalies of the upper and lower respiratory tract (severe tracheomalacia, trachea-esophageal fistula, diaphragmatic hernia, congenital lobar emphysema, congenital cystic adenomatoid malformation).

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Apnea
• Bronchiolitis
• Caffeine

Intervention

Drug:
• Caffeine citrate
Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
• Normal saline
Placebo with an equivalent volume of normal saline.

Locations

Country	Name	City	State
Qatar	Pediatric emergency center, Hamad Medical Corporation	Doha

Sponsors (1)

Lead Sponsor	Collaborator
Hamad Medical Corporation

Country where clinical trial is conducted

Qatar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy outcome in this double-blinded study was the time until last apnea episode in both groups.		2 year 8 mongths	No
Secondary	The proportion of patients with apnea resolution at 12 hours in both groups,		2 year and 8 months	No
Secondary	The frequency of apnea in the first 24, 48 and 72 hours after medication administration for both arms		2 year and 8 months	No
Secondary	The duration of apnea in the first 24, 48, and 72 hours after medication administration for both arms		2 year and 8 months	No
Secondary	Invasive and non-invasive respiratory support needed in both groups.		2 year 8 months	No
Secondary	The length of oxygen therapy needed in both groups.		2 year 8 months	No
Secondary	The time until feeding was tolerated in both groups.		2 year 8 months	No
Secondary	The length of PICU/step-down unit stay in both groups.		2 year 8 months	No
Secondary	The overall length of hospital stay in both groups.		2 year 8 months	No
Secondary	Spot heart rate in both groups was compared every 4 hours from enrollment for up to three days.	As a safety measure, spot heart rate was compared every 4 hours from enrollment for up to three days.	2 year 8 months	Yes